Table 3.
Susceptibility of the regimen and RT-PR associated resistance mutations
| Samplea | Backbone regimen | RT mutations | PR mutations | Susceptible drugs (including RAL)b |
|---|---|---|---|---|
| 2 | ETV + DRV/r | – | – | 3 |
| 3 | TDF + ZDV + LPV/r | – | – | 3 |
| 6 | TDF/FTC | M184V, V179D | – | 2 |
| 7 | TDF + DRV/r | K103N, Y318F | – | 3 |
| 8 | ETV + DRV/r + T20 | E44D, L210W, T215D, K103N, E138G, V179E | V32I, M46I, I54L, V82T, I84V, L33F, T74P | 2 |
| 11 | TDF/FTC + ETV | – | – | 4 |
| 12 | TDF + ZDV + T20 | K103N, V108I, H221Y | – | 4 |
| 13 | TDF/FTC + DRV/r | M41L, L74V, M184V, L210W, T215Y, K103S, G190A, F227L | M46L, I54V, I84V, L24M, Q58E | 1 |
| 14 | TDF/FTC | M41L, M184V, T215Y, K103N, K238T | – | 1 |
| 17 | ABC/3TC | M184V | – | 1 |
| 18 | ETV + DRV/r | M184V, K103N, M230L | L33F, M46I, I47V, I54M, V82M | 1 |
| 19 | TDF/FTC | M41L, E44D, D67N, L74V, M184V, L210W, T215Y, K219E, L100I, K103N | L90M | 2 |
| 21 | TPV/r + T20 | M41L, A62V, T69D, V75I, Y115F, F116Y, Q151M, M184V, L210W, T215Y, K219R, L100I, K103S, F22FL | V32I, M46I, I54V, V82F, I84V, L90M, L33F, K43T, T74P | 2 |
| 22 | ABC/3TC | M184MIV | – | 1 |
| 23 | TDF + LPV/r | M41L, T215Y | M46I, I54V, V82A, L24I | 1 |
| 24 | TDF/FTC + ATV/r | D67N, T215A, K219Q | – | 3 |
| 25 | EFV + DRV/r | M41L | – | 3 |
RT reverse transcriptase, PR protease, ETV etravirine, DRV/r darunavir and ritonavir, TDF tenofovir, ZDV zidovudine, LPV/r lopinavir and ritonavir, FTC emtricitabine, T20 enfuvirtide, ABC abacavir, 3TC lamivudine, TPV/r tipranavir and ritonavir, EFV efavirenz
aSamples from subjects with backbone resistance data available
bNumber of drugs with a predicted resistance score < 15 (T20 was considered susceptible for all cases). n = 17